Better science
better cancer detection
Easy to use, ex vivo and in vivo cancer detection that provides instantaneous, highly accurate results, without capital equipment.
NOVASCAN’S MISSION
Breakthrough Technology Improving Cancer Diagnosis
NovaScan’s leadership believes that improving the detection and stratification of cancer – be it in initial detection of cancer, during a procedure, or in post-procedural pathology – can improve patient outcomes, increase physician economics, and reduce the cost of care. We are committed to commercializing our platform technology for cancer detection and stratification, which we believe offers significant advantages over alternatives in soft tissue cancer detection. NovaScan’s first product, MarginScan Skin, offers dermatologists the opportunity for fast, predictable healthy tissue sparing skin cancer procedures.
NovaScan In the Press
NovaScan Awarded $3.7 Million CPRIT Grant to Advance MarginScan™ for Breast Cancer Surgery
NovaScan, Inc., an AI-enhanced cancer detection and treatment company, today announced that it has been awarded a $3.7 million non-dilutive grant from the Cancer Prevention and Research Institute of Texas (CPRIT).
Study Involving NovaScan’s Groundbreaking MarginScan™ Intraoperative Cancer Device Selected for Presentation at 2025 AAD Innovation Academy
NovaScan’s groundbreaking MarginScan™ device for real-time cancer detection during Mohs surgery has been selected for presentation at the 2025 AAD Innovation Academy’s “Future of Dermatology” session.
Clinical Results with NovaScan MarginScan™ Device to be Presented at Wisconsin Dermatology Society Meeting
NovaScan, a leader in point-of-care cancer detection and treatment technologies, is pleased to announce that its MarginScan™ device will be featured in a poster presentation at the Wisconsin Dermatology Society (WDS) Spring Meeting on April 26, 2025.